系统性硬化症相关间质性肺病患者的正在进行的临床试验和治疗选择
系统性硬化症(SSc)是一种可累及多器官系统的罕见结缔组织病,约80%的患者存在间质性肺病(ILD)证据,目前尚无获批的疾病修饰治疗。本文综述了针对SSc-ILD发病机制(纤维化和炎症通路、淋巴细胞、细胞间及细胞-细胞外膜相互作用)的已确立药物和新型药物的正在招募患者的临床试验。
要点
- 约80%的SSc患者存在ILD证据,目前尚无获批的疾病修饰治疗。
- 环磷酰胺(CYC)被纳入治疗指南,但疗效有限且伴有毒性。
- 霉酚酸酯(MMF)在北美和英国的临床实践中正成为最常用药物,但其使用并不普遍。
核心结论
- 针对SSc-ILD纤维化和炎症通路、淋巴细胞、细胞间及细胞-细胞外膜相互作用的新药有望改善肺功能、患者相关结局和生活质量。
研究设计与样本
- 综述了正在招募SSc-ILD患者的已确立药物和新型药物的临床试验。
主要发现
- 约80%的SSc患者存在ILD证据。
- CYC被纳入治疗指南,但疗效有限且伴有毒性。
- MMF在北美和英国的临床实践中正成为最常用药物,但其使用并不普遍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are available. CYC is included in treatment guidelines, but it has limited efficacy and is associated with toxicity. MMF is becoming the most commonly used medication in clinical practice in North America and the UK, but its use is not universal. Newer agents targeting the pathogenic mechanisms underlying SSc-ILD, including fibrotic and inflammatory pathways, lymphocytes, cell-cell and cell-extracellular membrane interactions, hold promise for better treatment outcomes, including improved lung function, patient-related outcomes and quality of life. Here we review ongoing trials of established and novel agents that are currently recruiting patients with SSc-ILD.
引用
- Khanna D, Tashkin DP, Denton CP, et al. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 2019. PMID: 29893938. doi:10.1093/rheumatology/key151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。